Search - tctmd.com

Displaying 1 - 20 of 253

Sort: Relevancy | Date

News Features

Repaso del Año: Los Médicos Eligen las Noticias Más Importantes de 2016 en Cardiología Intervencionista y Más

Shelley Wood

December 30, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular News and Features for 2016

Shelley Wood

December 29, 2016

News Opinion Editor's Corner

Las Noticias y Blogs Más Populares de TCTMD en 2016

Shelley Wood

December 29, 2016

News Daily News

Multiple Antithrombotic Meds Before PCI in NSTE ACS Ups Bleeding Risk, Lowers Survival

Michael O'Riordan

December 13, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2016

Shelley Wood

November 30, 2016

News Daily News

Tricky Population of Patients With A-fib Undergoing PCI Tackled in New Consensus Document

Todd Neale

November 29, 2016

News Conference News AHA 2016

Rivaroxaban-Based Double or Triple Therapy Cuts Bleeding in Patients With A-fib Undergoing PCI: PIONEER AF-PCI

Todd Neale

November 14, 2016

News Daily News

Registry Data Show Rise and Fall of Bivalirudin vs Heparin for Primary PCI

Yael L. Maxwell

November 11, 2016

News Daily News

Datos de Registro Revelan el Ascenso y Caída de la Bivalirudina frente a la Heparina en la Realización de PCI Primarias

Yael L. Maxwell

November 11, 2016

News Conference News AHA 2016

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

Shelley Wood

November 09, 2016

News Conference News TCT 2016

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Yael L. Maxwell

October 31, 2016

Presentation TCT 2016

Start With a Three-way Debate: Bivalirudin Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Presenter: A. Michael Lincoff, Franz-Josef Neumann, Harvey D. White

October 30, 2016

Presentation TCT 2016

Start With a Three-way Debate: Heparin Plus Routine Use of GP IIb/IIIa Inhibitors Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Presenter: A. Michael Lincoff, Franz-Josef Neumann, Jorge F. Saucedo

October 30, 2016

Presentation TCT 2016

Start With a Three-way Debate: Heparin Monotherapy Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Presenter: A. Michael Lincoff, Franz-Josef Neumann

October 30, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2016

Caitlin E. Cox

October 29, 2016

News Daily News

Oral Anticoagulation Use Common in PCI Patients, With Triple Therapy the Norm at Discharge

Todd Neale

October 18, 2016

News Daily News

No Differences Between Bivalirudin, Unfractionated Heparin in ACS Patients With or Without ST Elevation: MATRIX

Shelley Wood

October 03, 2016

News Daily News

MATRIX: No Hay Diferencias entre Bivalirudina y Heparina No Fraccionada en Pacientes SCA Con o Sin Elevación del Segmento ST

Shelley Wood

October 03, 2016

News Daily News

Trends in Cardiovascular Drug Development Speak to Pipeline Problems and Possibilities

Caitlin E. Cox

September 08, 2016

News Daily News

Las Tendencias en el Desarrollo de Fármacos Cardiovasculares Indican Problemas y Posibilidades Durante la Fase de Desarrollo

Caitlin E. Cox

September 08, 2016

Advertisement

Repaso del Año: Los Médicos Eligen las Noticias Más Importantes de 2016 en Cardiología Intervencionista y Más

TCTMD’s Top 10 Most Popular News and Features for 2016

Las Noticias y Blogs Más Populares de TCTMD en 2016

Multiple Antithrombotic Meds Before PCI in NSTE ACS Ups Bleeding Risk, Lowers Survival

TCTMD’s Top 10 Most Popular Stories for November 2016

Tricky Population of Patients With A-fib Undergoing PCI Tackled in New Consensus Document

Rivaroxaban-Based Double or Triple Therapy Cuts Bleeding in Patients With A-fib Undergoing PCI: PIONEER AF-PCI

Registry Data Show Rise and Fall of Bivalirudin vs Heparin for Primary PCI

Datos de Registro Revelan el Ascenso y Caída de la Bivalirudina frente a la Heparina en la Realización de PCI Primarias

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Start With a Three-way Debate: Bivalirudin Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Start With a Three-way Debate: Heparin Plus Routine Use of GP IIb/IIIa Inhibitors Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Start With a Three-way Debate: Heparin Monotherapy Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

TCTMD’s Top 10 Most Popular Stories for October 2016

Oral Anticoagulation Use Common in PCI Patients, With Triple Therapy the Norm at Discharge

No Differences Between Bivalirudin, Unfractionated Heparin in ACS Patients With or Without ST Elevation: MATRIX

MATRIX: No Hay Diferencias entre Bivalirudina y Heparina No Fraccionada en Pacientes SCA Con o Sin Elevación del Segmento ST

Trends in Cardiovascular Drug Development Speak to Pipeline Problems and Possibilities

Las Tendencias en el Desarrollo de Fármacos Cardiovasculares Indican Problemas y Posibilidades Durante la Fase de Desarrollo

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content